EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Perioperative and oncologic outcomes with robotic vs. open radical prostatectomy

Amanda E. Hird, Rano Matta, Sarah Neu, Janine Xu, Tharsiya Martin, Amber Hunter, Girish S. Kulkarni, Paul Karanicolas, Natalie Coburn, Robert K. Nam, Sender Herschorn, Frances C. Wright

Canadian Urological Association Journal · 2026-10-19 · 21 (2)

DOI: 10.5489/cuaj.9708 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Robotic-assisted radical prostatectomy (RARP) is the predominant surgical treatment for localized prostate cancer worldwide, but adoption has been slower in Ontario due to funding constraints. This setting enables population-level comparison of RARP and open radical prostatectomy (ORP). We evaluated perioperative and short-term oncologic outcomes for men undergoing radical prostatectomy in Ontario between April 2017 and March 2024. Methods: We conducted a retrospective cohort study of all patients who underwent publicly funded radical prostatectomy for localized prostate cancer. Co-primary outcomes were blood transfusion rates and hospital length of stay (LOS). Secondary outcomes included operative time, 30-day readmission, vesico-urethral anastomosis stenosis (VUAS) requiring intervention, surgical wait time, and travel distance. Exploratory outcomes included 30-day mortality, positive surgical margins (PSM), and receipt of pelvic radiation post-prostatectomy. Results: Among 15 073 patients, 6645 (44.1%) underwent RARP and 8428 (55.9%) ORP. Median followup was 36.8 months after RARP and 38.8 months after ORP. RARP was associated with lower transfusion rates (1.2% vs. 4.7%, p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →